Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

Tofacitinib 5mg oral table twice daily for 16 weeks

Spirometry testing at baseline, week 4, week 8, week 12, and week 16

RNA sequencing test at baseline and week 16

Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16

Taper corticosteroids starting at week 4

After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.